CLAIMS

1. Compound corresponding to formula (I):

(I)

in which:

the representation of the pyrazole ring indicates that the substituent R_4 may be borne either by the nitrogen alpha to the pyridine ring (I') or by the nitrogen alpha to the carbon bearing a substituent R_3 (I'') such that:



(I')

Either



(I'')

- **R_1** represents an aryl, pyridyl or pyrazolyl group optionally substituted with one or more substituents chosen from:
  - a fluorine atom,
  - a $-CF_3$ group,
  - a cyano group,
  - a group $-NR_6R_6'$ in which R_6 and R_6' are as defined below,
  - a group $-NR_{10}R_{11}$ such that R_{10} and R_{11} form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom, optionally

substituted with one or more substituents chosen from a halogen atom and a linear or branched alkyl group,

- a group $-CH_2NR_{10}R_{11}$ such that R_{10} and R_{11} form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,
- a group $-COR_{12}$ in which R_{12} represents a hydroxyl group or a group $-NR_6R_6'$, in which R_6 and R_6' are as defined below,
- a group $-CONR_7R_7'$ such that R_7 and R_7' form, together with the nitrogen atom to which they are attached, a heterocycloalkyl comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,
- a group $-(CH_2)_pNHSO_2CH_3$ in which p represents 0 or 1,
- a group $-OR_{13}$ in which R_{13} represents a linear group $(C_1$-$C_3)$alkyl,
- a group $(C_1$-$C_3)$alkyl,

Or R_1 represents a bicyclic group of formula A below:



(A)

in which R_8 and R_9 form, together with the carbon atoms to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom, an oxygen atom and a sulfur atom, optionally substituted with one or more linear alkyl groups,

- **R_2** represents:
  - a $-CF_3$ group,
  - a $-CHF_2$ group,

- or
  - a group $-CONHR_5$, in which R_5 is as defined below,

- **R_3** represents:

- a hydrogen atom,
- an aryl group, optionally substituted with an alkoxymethyl group,

or

- a heteroaryl group chosen from thienyl and pyridyl groups,

➢ **R_4** represents:

- a hydrogen atom,
- a (C_1)alkyl, linear (C_3)alkyl, or linear (C_1-C_3)alkyl , substituted with a group -NR_6R_6' in which R_6 and R'_6 are as defined below or a group –$NR_7R_{7'}$' such that R_7 and $R_{7'}$ form, together with the nitrogen atom to which they are attached, a heterocycloalkyl comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,

➢ **R_5** represents:

- a hydrogen atom,
- a linear group (C_1-C_3)alkyl, optionally substituted with a pyridyl group,

  or
- an aromatic group chosen from aryl and pyridyl,

➢ **R_6** and **R'_6**, which may be identical or different, represent a hydrogen atom or a linear alkyl group,

in the form of the base or of an acid-addition or base-addition salt,

with the exception of the following compounds:

2-Fluoro-5-(3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzoic acid;

3-(1-Methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzamide;

N-[4-(1-Methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzyl]methanesulfonamide;

1-Methyl-6-(1-methyl-1H-indol-6-yl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;

N-[3-(1-Methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]methanesulfonamide;

4-Methyl-7-(1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-3,4-

dihydro-2H-benzo[1,4]oxazine;
N-[3-(1-Methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzyl]methanesulfonamide;
6-(4-Methoxyphenyl)-1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
2-Fluoro-N-methyl-5-(1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzamide;
Dimethyl[3-(1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]amine;
6-[4-(3,5-Dimethylpyrazol-1-yl)phenyl]-1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
1-Methyl-6-(3-morpholin-4-ylmethylphenyl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
5-(1-Methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)nicotinonitrile;
4-(1-Methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzoic acid;
N,N-Dimethyl-4-(1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzamide;
N,N-Dimethyl-3-(1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzamide;
1-Methyl-6-(6-morpholin-4-ylpyridin-3-yl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
6-(6-Methoxypyridin-3-yl)-1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
1-Methyl-3-phenyl-6-(6-pyrrolidin-1-ylpyridin-3-yl)-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
1-Methyl-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
6-Benzothiazol-5-yl-1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
N,N-Dimethyl-4-(3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzamide;
6-(4-Morpholin-4-ylphenyl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
6-(6-Morpholin-4-ylpyridin-3-yl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
6-(6-Methoxypyridin-3-yl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
6-(3-Morpholin-4-ylphenyl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;

N-Methyl-3-(3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzamide;
N-[3-(3-Phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]methanesulfonamide;
3-Phenyl-6-(3-piperidin-1-ylphenyl)-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
2-Fluoro-N-methyl-5-(3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzamide;
5-(3-Phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)nicotinonitrile;
2-Fluoro-5-(1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzoic acid;
2-Amino-5-(4-difluoromethyl-2-methyl-2H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
Dimethyl[4-(3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]amine;
4-(3-Phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenylamine;
6-(4-Methoxyphenyl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
in the form of the base or of an acid-addition or base-addition salt.

2. Compounds of formula (I) according to Claim 1, characterized in that $\mathbf{R_2}$ represents a group:

- $-CHF_2$, except when R_4 located on the nitrogen alpha to R_3 represents a methyl group and R_3 represents a hydrogen atom,

or

- $-CONHR_5$, in which R_5 represents a hydrogen atom or a linear group $(C_1\text{-}C_3)$alkyl, optionally substituted with a pyridyl group or an aromatic group chosen from aryl and pyridyl,

in the form of the base or of an acid-addition or base-addition salt.

3. Compounds of formula (I) according to any one of Claims 1 or 2, characterized in that $\mathbf{R_1}$ represents an aryl, pyridyl or pyrazolyl group, optionally substituted with one or more substituents chosen from:

- a fluorine atom,

and

- a group $-COR_{12}$, in which R_{12} represents a hydroxyl group,

in the form of the base or of an acid-addition or base-addition salt.

4. Compounds of formula (I) according to Claims 1 to 3, characterized in that R_1 represents an aryl group, in the form of the base or of an acid-addition or base-addition salt.

5. Compounds of formula (I) according to any one of Claims 1, 3 and 4, characterized in that R_2 represents:

- a $-CF_3$ group,
- a $-CHF_2$ group,

or

- a group $-CONHR_5$, in which R_5 represents a hydrogen atom or a linear group (C_1-C_3)alkyl, optionally substituted with a pyridyl group or an aromatic group chosen from aryl and pyridyl,

in the form of the base or of an acid-addition or base-addition salt.

6. Compound of formula (I) according to one of the preceding claims, characterized in that it is chosen from the following compounds:
[4-(4-Difluoromethyl-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]pyrrolidin-1-ylmethanone;
4-Difluoromethyl-6-(1-methyl-1H-pyrazol-4-yl)-3-phenyl-1H-pyrazolo[3,4-b]pyridine;
4-Difluoromethyl-6-(3,5-dimethyl-1H-pyrazol-4-yl)-3-phenyl-1H-pyrazolo[3,4-b]pyridine;
4-Difluoromethyl-3-phenyl-6-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine;
4-Difluoromethyl-6-(6-methoxypyridin-3-yl)-3-phenyl-1H-pyrazolo[3,4-b]pyridine;
[3-(4-Difluoromethyl-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]pyrrolidin-1-ylmethanone;
4-Difluoromethyl-3-phenyl-6-(3-piperidin-1-ylphenyl)-1H-pyrazolo[3,4-b]pyridine;

6-(4-Amino-3-methoxyphenyl)-3-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid methylamide;
6-(4-Amino-3-methoxyphenyl)-3-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide;
6-(4-Amino-3-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid methylamide;

4-(4-Amino-3-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid methylamide;
6-(4-Amino-3-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide;
6-(4-Amino-3-methoxyphenyl)-2-methyl-2H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide;
5-(4-Carbamoyl-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-2-fluorobenzoic acid;
2-Amino-5-(4-carbamoyl-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzoic acid;
6-(4-Amino-3-cyanophenyl)-3-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide;
6-(4-Amino-3-cyanophenyl)-3-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide;
6-(4-Amino-3-cyanophenyl)-3-thiophen-2-yl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide;
5-(4-Carbamoyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-2-fluorobenzoic acid;
6-(3-Cyano-4-fluorophenyl)-3-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide;
5-(4-Difluoromethyl-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-2-fluorobenzoic acid;
2-Fluoro-5-(3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
2-Amino-5-(4-difluoromethyl-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
2-Amino-5-(1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
6-(3-Carbamoyl-4-fluorophenyl)-3-pyridin-3-yl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide;
5-(4-Difluoromethyl-2-methyl-2H-pyrazolo[3,4-b]pyridin-6-yl)-2-fluorobenzonitrile;
6-(1H-Indol-6-yl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
5-(3-Phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-1,3-dihydrobenzimidazol-2-one;
6-(4-Amino-3-cyanophenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid phenylamide;
6-(4-Amino-3-cyanophenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid (pyridin-2-ylmethyl)amide;
6-(4-Amino-3-cyanophenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid pyridin-2-ylamide;
6-(4-Amino-3-cyanophenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid pyridin-3-ylamide;

6-(4-Amino-3-cyanophenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid pyridin-4-ylamide;
5-(4-Difluoromethyl-2-methyl-2H-pyrazolo[3,4-b]pyridin-6-yl)-2-fluorobenzamide;
5-(4-Difluoromethyl-1-methyl-3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-2-fluorobenzonitrile;
2-Amino-5-(2-methyl-3-phenyl-4-trifluoromethyl-2H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
6-(1H-Benzimidazol-5-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid phenylamide;
6-(1H-Benzimidazol-5-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid pyridin-2-ylamide;
6-(1H-Benzimidazol-5-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid (pyridin-3-ylmethyl)amide;
6-(2-Oxo-2,3-dihydro-1H-benzimidazol-5-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid phenylamide;
2-Amino-5-(4-difluoromethyl-1-methyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
3-(4-Difluoromethyl-1-methyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
4-(4-Difluoromethyl-1-methyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenylamine;
2-Amino-5-[2-(2-dimethylaminoethyl)-3-phenyl-4-trifluoromethyl-2H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile;
2-Amino-5-(4-difluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
2-Amino-5-[1-(2-dimethylaminoethyl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile;
2-Amino-5-[2-(2-morpholin-4-ylethyl)-3-phenyl-4-trifluoromethyl-2H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile;
2-Methoxy-5-(1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)nicotinonitrile;
2-Amino-5-(4-difluoromethyl-1-methyl-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
4-(4-Difluoromethyl-1-methyl-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenylamine;
[3-(4-Difluoromethyl-1-methyl-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]dimethylamine;
2-Amino-5-[3-phenyl-1-(2-piperidin-1-ylethyl)-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile;
Dimethyl{3-[3-phenyl-1-(2-piperidin-1-ylethyl)-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl}amine;

2-Amino-5-[4-difluoromethyl-2-(2-dimethylaminoethyl)-2H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile;
2-Amino-5-[4-difluoromethyl-2-(2-morpholin-4-ylethyl)-2H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile;
2-Amino-5-[4-difluoromethyl-1-(2-dimethylaminoethyl)-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile;
2-(2-Morpholin-4-ylethyl)-6-(3-morpholin-4-ylmethylphenyl)-4-trifluoromethyl-2H-pyrazolo[3,4-b]pyridine;
Dimethyl{3-[1-(2-morpholin-4-ylethyl)-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl}amine;
5-[1-(2-Morpholin-4-ylethyl)-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl]nicotinonitrile;
5-[1-(2-Morpholin-4-ylethyl)-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl]nicotinamide;
2-Amino-5-(2-methyl-4-trifluoromethyl-2H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
1-Methyl-6-(3-morpholin-4-ylmethylphenyl)-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
2-Amino-5-(1-methyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
Dimethyl[3-(1-methyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]amine;
Dimethyl[3-(3-phenyl-2-propyl-4-trifluoromethyl-2H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]amine;
2-Amino-5-[4-difluoromethyl-2-(2-piperidin-1-ylethyl)-2H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile;
2-Amino-5-(4-difluoromethyl-3-pyridin-3-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
2-Amino-5-(4-difluoromethyl-2-propyl-2H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
2-Amino-5-(4-difluoromethyl-3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
1-Methyl-6-(3-morpholin-4-ylmethylphenyl)-3-pyridin-3-yl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
2-Amino-5-[4-difluoromethyl-3-(3-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile;
2-Amino-5-(2-propyl-4-trifluoromethyl-2H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
6-(3-Morpholin-4-ylmethylphenyl)-2-propyl-4-trifluoromethyl-2H-pyrazolo[3,4-b]pyridine;

Dimethyl[3-(2-propyl-4-trifluoromethyl-2H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]amine;
6-(3-Morpholin-4-ylmethylphenyl)-1-propyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
6-(4-Methoxyphenyl)-1-propyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
5-[3-(3-Methoxyphenyl)-1-methyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl]nicotinonitrile;
3-(3-Methoxyphenyl)-1-methyl-6-(3-morpholin-4-ylmethylphenyl)-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
{3-[3-(3-Methoxyphenyl)-1-methyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl}dimethylamine;
3-(3-Methoxyphenyl)-6-(4-methoxyphenyl)-1-methyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine.

7. Process for preparing the compounds of formula (I) according to Claim 1, in which R_2 represents a group $-CHF_2$ or $-CF_3$; R_1, R_3 and R_4 are as defined previously, with the exception of R_3 and R_4 representing a hydrogen atom, characterized in that:

- the compound of formula (XV) is subjected to an iodination reaction in the presence of N-iodosuccinimide in order to obtain the compound of formula (XVIII),
- the compound of formula (XVIII) is then subjected to an alkylation reaction in the presence of a halogenated derivative of formula R_4-X in order to obtain the compounds of formulae (XIX) and (XX),
- the compounds of formulae (XIX) and (XX) are separately subjected, in the presence of a palladium catalyst, a ligand and a base, to a reaction with phenylboronic or heteroarylboronic derivatives or phenylboronate esters or heteroarylboronate esters according to a Suzuki coupling, in order to obtain the compounds of formulae (XXI) and (XXII),
- the compounds of formulae (XXI) and (XXII) are separately subjected, in the presence of a palladium catalyst, a ligand and a base, to a reaction with phenylboronic or heteroarylboronic derivatives or phenylboronate esters or heteroarylboronate esters according to a Suzuki coupling, in order to obtain the compound of formula (I) in which R_2 represents a group $-CHF_2$ or $-CF_3$; R_1, R_3 and R_4 are as defined previously.

8. Process for preparing the compounds of formula (I) according to Claim 1,

in which R_2 represents a group $-CHF_2$ or $-CF_3$, R_1 and R_3 are as defined previously, with the exception of R_3 representing a hydrogen atom, characterized in that:

- the compound of formula (XVIII) is subjected to an alkylation reaction in the presence of a protecting group P in order to obtain the compound of formula (XXIII),
- the compound of formula (XXIII) is subjected to a reaction with phenylboronic or heteroarylboronic derivatives or phenylboronate esters or heteroarylboronate esters according to a Suzuki coupling, in order to obtain the compound of formula (XXIV),
- the compound of formula (XXIV) is subjected to a reaction with phenylboronic or heteroarylboronic derivatives or phenylboronate esters or heteroarylboronate esters according to a Suzuki coupling, in order to obtain the compound of formula (XXV),
- the compound of formula (XXV) is subjected to a deprotection reaction in order to obtain the compound of formula (I) in which R_2 represents a group $-CHF_2$ or $-CF_3$..

9. Medicament, characterized in that it comprises a compound of formula (I):

(I)

in which:

the representation of the pyrazole ring indicates that the substituent R_4 may be borne either by the nitrogen alpha to the pyridine ring (I') or by the nitrogen alpha to the carbon bearing a substituent R_3 (I'') such that:



(I')

Either

(I'')

- **R_1** represents an aryl, pyridyl or pyrazolyl group optionally substituted with one or more substituents chosen from:
    - a halogen atom,
    - a -CF_3 group,
    - a cyano group,
    - a group -NR_6R_6' in which R_6 and R_6' are as defined below,
    - a group -$NR_{10}R_{11}$ such that R_{10} and R_{11} form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom, optionally substituted with one or more substituents chosen from a halogen atom and a linear or branched alkyl group,
    - a group -$CH_2NR_{10}R_{11}$ such that R_{10} and R_{11} form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,
    - a group –COR_{12} in which R_{12} represents a hydroxyl group or a group –NR_6R_6', in which R_6 and R_6' are as defined below,
    - a group -$CONR_7R_7'$ such that R_7 and R_7' form, together with the nitrogen atom to which they are attached, a heterocycloalkyl comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,
    - a group –$(CH_2)_pNHSO_2CH_3$ in which p represents 0 or 1,
    - a group –OR_{13} in which R_{13} represents a linear group (C_1-C_3)alkyl,
    - a group (C_1-C_3)alkyl,

Or R_1 represents a bicyclic group of formula A below:



(A)

in which R_8 and R_9 form, together with the carbon atoms to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom, an oxygen atom and a sulfur atom, optionally substituted with one or more linear alkyl groups,

- **R_2** represents:
  - a $-CF_3$ group,
  - a $-CHF_2$ group,
  - a –COOH group,
  - or
  - a group $–CONHR_5$, in which R_5 is as defined below,

- **R_3** represents:
  - a hydrogen atom,
  - an aryl group, optionally substituted with an alkoxymethyl group,
  - a cycloalkyl group,

or

  - a heteroaryl group chosen from thienyl and pyridyl groups,

- **R_4** represents:
  - a hydrogen atom,
  - a linear group $(C_1\text{-}C_3)$alkyl, optionally substituted with a group $-NR_6R_6'$ in which R_6 and R'_6 are as defined below or a group $–NR_7R_{7'}$ such that R_7 and $R_{7'}$ form, together with the nitrogen atom to which they are attached, a heterocycloalkyl comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,

- **R_5** represents:
  - a hydrogen atom,
  - a linear group $(C_1\text{-}C_3)$alkyl, optionally substituted with a pyridyl group,

or

- an aromatic group chosen from aryl and pyridyl,

R_6 and R'_6, which may be identical or different, represent a hydrogen atom or a linear alkyl group or a pharmaceutically acceptable acid-addition or base-addition salt of this compound.

10. Compounds of formula (I)

(I)

in which:

the representation of the pyrazole ring indicates that the substituent R_4 may be borne either by the nitrogen alpha to the pyridine ring (I') or by the nitrogen alpha to the carbon bearing a substituent R_3 (I'') such that:



(I')

Either



(I'')

- R_1 represents an aryl, pyridyl or pyrazolyl group optionally substituted with one or more substituents chosen from:
  - a halogen atom,
  - a $-CF_3$ group,
  - a cyano group,
  - a group $-NR_6R_6'$ in which R_6 and R_6' are as defined below,
  - a group $-NR_{10}R_{11}$ such that R_{10} and R_{11} form, together with

the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom, optionally substituted with one or more substituents chosen from a halogen atom and a linear or branched alkyl group,

- a group $-CH_2NR_{10}R_{11}$ such that R_{10} and R_{11} form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,
- a group $-COR_{12}$ in which R_{12} represents a hydroxyl group or a group $-NR_6R_6'$, in which R_6 and R_6' are as defined below,
- a group $-CONR_7R_7'$ such that R_7 and R_7' form, together with the nitrogen atom to which they are attached, a heterocycloalkyl comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,
- a group $-(CH_2)_pNHSO_2CH_3$ in which p represents 0 or 1,
- a group $-OR_{13}$ in which R_{13} represents a linear group (C_1-C_3)alkyl,
- a group (C_1-C_3)alkyl,

Or R_1 represents a bicyclic group of formula A below:



(A)

in which R_8 and R_9 form, together with the carbon atoms to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom, an oxygen atom and a sulfur atom, optionally substituted with one or more linear alkyl groups,

- **R_2** represents:
  - a $-CF_3$ group,
  - a $-CHF_2$ group,
  - a –COOH group,
- or

- a group –CONHR$_5$, in which R$_5$ is as defined below,

➢ **R$_3$** represents:
- a hydrogen atom,
- an aryl group, optionally substituted with an alkoxymethyl group,
- a cycloalkyl group,

or

- a heteroaryl group chosen from thienyl and pyridyl groups,

➢ **R$_4$** represents:
- a hydrogen atom,
- a linear group (C$_1$-C$_3$)alkyl, optionally substituted with a group -NR$_6$R$_6$' in which R$_6$ and R'$_6$ are as defined below or a group –NR$_7$R$_{7'}$' such that R$_7$ and R$_{7'}$ form, together with the nitrogen atom to which they are attached, a heterocycloalkyl comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,

➢ **R$_5$** represents:
- a hydrogen atom,
- a linear group (C$_1$-C$_3$)alkyl, optionally substituted with a pyridyl group,

or
- an aromatic group chosen from aryl and pyridyl,

➢ **R$_6$** and **R'$_6$**, which may be identical or different, represent a hydrogen atom or a linear alkyl group,

in the form of the base or of an acid-addition or base-addition salt, as medicaments.

11. Pharmaceutical composition, characterized in that it comprises a compound of formula (I)

(I)

in which:

the representation of the pyrazole ring indicates that the substituent R_4 may be borne either by the nitrogen alpha to the pyridine ring (I') or by the nitrogen alpha to the carbon bearing a substituent R_3 (I'') such that:



(I')

Either



(I'')

- **R_1** represents an aryl, pyridyl or pyrazolyl group optionally substituted with one or more substituents chosen from:
  - a halogen atom,
  - a $-CF_3$ group,
  - a cyano group,
  - a group $-NR_6R_6'$ in which R_6 and R_6' are as defined below,
  - a group $-NR_{10}R_{11}$ such that R_{10} and R_{11} form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom, optionally substituted with one or more substituents chosen from a halogen atom and a linear or branched alkyl group,
  - a group $-CH_2NR_{10}R_{11}$ such that R_{10} and R_{11} form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,
  - a group $-COR_{12}$ in which R_{12} represents a hydroxyl group or a

group $-NR_6R_6'$, in which R_6 and R_6' are as defined below,

- a group $-CONR_7R_7'$ such that R_7 and R_7' form, together with the nitrogen atom to which they are attached, a heterocycloalkyl comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,
- a group $-(CH_2)_pNHSO_2CH_3$ in which p represents 0 or 1,
- a group $-OR_{13}$ in which R_{13} represents a linear group $(C_1\text{-}C_3)$alkyl,
- a group $(C_1\text{-}C_3)$alkyl,

Or R_1 represents a bicyclic group of formula A below:



(A)

in which R_8 and R_9 form, together with the carbon atoms to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom, an oxygen atom and a sulfur atom, optionally substituted with one or more linear alkyl groups,

- **R_2** represents:
  - a $-CF_3$ group,
  - a $-CHF_2$ group,
  - a –COOH group,
- or
  - a group $-CONHR_5$, in which R_5 is as defined below,

- **R_3** represents:
  - a hydrogen atom,
  - an aryl group, optionally substituted with an alkoxymethyl group,
  - a cycloalkyl group,

or

  - a heteroaryl group chosen from thienyl and pyridyl groups,

- **R_4** represents:
  - a hydrogen atom,

- a linear group (C_1-C_3)alkyl, optionally substituted with a group -NR_6R_6' in which R_6 and R'_6 are as defined below or a group –$NR_7R_{7'}$ such that R_7 and $R_{7'}$ form, together with the nitrogen atom to which they are attached, a heterocycloalkyl comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,

- **R_5** represents:
  - a hydrogen atom,
  - a linear group (C_1-C_3)alkyl, optionally substituted with a pyridyl group,
    or
  - an aromatic group chosen from aryl and pyridyl,

- **R_6** and **R'_6**, which may be identical or different, represent a hydrogen atom or a linear alkyl group,

in the form of the base or of an acid-addition or base-addition salt, and also at least one pharmaceutically acceptable excipient.

12. Compound of formula (I)

(I)

in which:

the representation of the pyrazole ring indicates that the substituent R_4 may be borne either by the nitrogen alpha to the pyridine ring (I') or by the nitrogen alpha to the carbon bearing a substituent R_3 (I'') such that:



(I')

Either

(I'')

- R_1 represents an aryl, pyridyl or pyrazolyl group optionally substituted with one or more substituents chosen from:
    - a halogen atom,
    - a $-CF_3$ group,
    - a cyano group,
    - a group $-NR_6R_6'$ in which R_6 and R_6' are as defined below,
    - a group $-NR_{10}R_{11}$ such that R_{10} and R_{11} form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom, optionally substituted with one or more substituents chosen from a halogen atom and a linear or branched alkyl group,
    - a group $-CH_2NR_{10}R_{11}$ such that R_{10} and R_{11} form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,
    - a group $-COR_{12}$ in which R_{12} represents a hydroxyl group or a group $-NR_6R_6'$, in which R_6 and R_6' are as defined below,
    - a group $-CONR_7R_7'$ such that R_7 and R_7' form, together with the nitrogen atom to which they are attached, a heterocycloalkyl comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,
    - a group $-(CH_2)_pNHSO_2CH_3$ in which p represents 0 or 1,
    - a group $-OR_{13}$ in which R_{13} represents a linear group $(C_1$-$C_3)$alkyl,
    - a group $(C_1$-$C_3)$alkyl,

Or R_1 represents a bicyclic group of formula A below:



(A)

in which R_8 and R_9 form, together with the carbon atoms to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom, an oxygen atom and a sulfur atom, optionally substituted with one or more linear alkyl groups,

- **R_2** represents:
  - a $-CF_3$ group,
  - a $-CHF_2$ group,
  - a –COOH group,
  - or
  - a group $–CONHR_5$, in which R_5 is as defined below,

- **R_3** represents:
  - a hydrogen atom,
  - an aryl group, optionally substituted with an alkoxymethyl group,
  - a cycloalkyl group,

or

  - a heteroaryl group chosen from thienyl and pyridyl groups,

- **R_4** represents:
  - a hydrogen atom,
  - a linear group $(C_1\text{-}C_3)$alkyl, optionally substituted with a group $-NR_6R_6'$ in which R_6 and R'_6 are as defined below or a group $–NR_7R_{7'}$ such that R_7 and $R_{7'}$ form, together with the nitrogen atom to which they are attached, a heterocycloalkyl comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,

- **R_5** represents:
  - a hydrogen atom,
  - a linear group $(C_1\text{-}C_3)$alkyl, optionally substituted with a pyridyl group,

or

- an aromatic group chosen from aryl and pyridyl,

➢ **R_6** and **R'_6**, which may be identical or different, represent a hydrogen atom or a linear alkyl group,

in the form of the base or of an acid-addition or base-addition salt, for its use in the treatment and prevention of cancers, especially carcinomas with a substantial degree of vascularization such as lung, breast, prostate, pancreatic, bowel, kidney and oesophageal carcinomas, cancers that induce metastases, such as bowel cancer, liver cancer and stomach cancer, melanomas, gliomas, lymphomas and leukaemias, and also thrombopenias.

13. Compound of formula (I)

(I)

in which:

the representation of the pyrazole ring indicates that the substituent R_4 may be borne either by the nitrogen alpha to the pyridine ring (I') or by the nitrogen alpha to the carbon bearing a substituent R_3 (I'') such that:



(I')

Either

(I'')

➢ **R_1** represents an aryl, pyridyl or pyrazolyl group optionally substituted with one or more substituents chosen from:

- a halogen atom,
- a $-CF_3$ group,
- a cyano group,
- a group $-NR_6R_6'$ in which R_6 and R_6' are as defined below,
- a group $-NR_{10}R_{11}$ such that R_{10} and R_{11} form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom, optionally substituted with one or more substituents chosen from a halogen atom and a linear or branched alkyl group,
- a group $-CH_2NR_{10}R_{11}$ such that R_{10} and R_{11} form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,
- a group $-COR_{12}$ in which R_{12} represents a hydroxyl group or a group $-NR_6R_6'$, in which R_6 and R_6' are as defined below,
- a group $-CONR_7R_7'$ such that R_7 and R_7' form, together with the nitrogen atom to which they are attached, a heterocycloalkyl comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,
- a group $-(CH_2)_pNHSO_2CH_3$ in which p represents 0 or 1,
- a group $-OR_{13}$ in which R_{13} represents a linear group $(C_1$-$C_3)$alkyl,
- a group $(C_1$-$C_3)$alkyl,

Or R_1 represents a bicyclic group of formula A below:



(A)

in which R_8 and R_9 form, together with the carbon atoms to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom, an oxygen atom and a sulfur atom, optionally substituted with one or more linear alkyl groups,

- **R_2** represents:
  - a $-CF_3$ group,
  - a $-CHF_2$ group,
  - a –COOH group,
  - or
  - a group $–CONHR_5$, in which R_5 is as defined below,

- **R_3** represents:
  - a hydrogen atom,
  - an aryl group, optionally substituted with an alkoxymethyl group,
  - a cycloalkyl group,

or

  - a heteroaryl group chosen from thienyl and pyridyl groups,

- **R_4** represents:
  - a hydrogen atom,
  - a linear group $(C_1\text{-}C_3)$alkyl, optionally substituted with a group $-NR_6R_6'$ in which R_6 and R'_6 are as defined below or a group $–NR_7R_{7'}$' such that R_7 and $R_{7'}$ form, together with the nitrogen atom to which they are attached, a heterocycloalkyl comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,

- **R_5** represents:
  - a hydrogen atom,
  - a linear group $(C_1\text{-}C_3)$alkyl, optionally substituted with a pyridyl group,

or

  - an aromatic group chosen from aryl and pyridyl,

- **R_6** and **R'_6**, which may be identical or different, represent a hydrogen atom or a linear alkyl group,

in the form of the base or of an acid-addition or base-addition salt, for its use in the treatment and prevention of cardiovascular diseases such as atherosclerosis, post-angioplasty restenosis, diseases associated with complications arising after the insertion of endovascular prostheses and/or aorto-coronary bypasses or other vascular grafts, cardiac hypotrophy, vascular complications of diabetes such as

diabetic retinopathy, hepatic, renal and pulmonary fibroses, neuropathic pain, chronic inflammatory diseases such as rheumatoid arthritis or IBD, prostate hyperplasia, psoriasis, clear-cell acanthoma, osteoarthritis, achondroplasias (ACH), hypochondroplasias (HCH), TD (thanatophoric dysplasia), obesity, and macular degeneration, such as age-related macular degeneration (AMD).

14. Use of a Compound of formula (I)



(I)

in which:

the representation of the pyrazole ring indicates that the substituent R_4 may be borne either by the nitrogen alpha to the pyridine ring (I') or by the nitrogen alpha to the carbon bearing a substituent R_3 (I'') such that:



(I')

Either

(I'')

- **R_1** represents an aryl, pyridyl or pyrazolyl group optionally substituted with one or more substituents chosen from:
  - a halogen atom,
  - a -CF_3 group,
  - a cyano group,
  - a group -NR_6R_6' in which R_6 and R_6' are as defined below,
  - a group -$NR_{10}R_{11}$ such that R_{10} and R_{11} form, together with

the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom, optionally substituted with one or more substituents chosen from a halogen atom and a linear or branched alkyl group,

- a group $-CH_2NR_{10}R_{11}$ such that R_{10} and R_{11} form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,
- a group $-COR_{12}$ in which R_{12} represents a hydroxyl group or a group $-NR_6R_6'$, in which R_6 and R_6' are as defined below,
- a group $-CONR_7R_7'$ such that R_7 and R_7' form, together with the nitrogen atom to which they are attached, a heterocycloalkyl comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,
- a group $-(CH_2)_pNHSO_2CH_3$ in which p represents 0 or 1,
- a group $-OR_{13}$ in which R_{13} represents a linear group $(C_1$-$C_3)$alkyl,
- a group $(C_1$-$C_3)$alkyl,

Or R_1 represents a bicyclic group of formula A below:



(A)

in which R_8 and R_9 form, together with the carbon atoms to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom, an oxygen atom and a sulfur atom, optionally substituted with one or more linear alkyl groups,

- **R_2** represents:
  - a $-CF_3$ group,
  - a $-CHF_2$ group,
  - a –COOH group,
- or

- a group –CONHR$_5$, in which R$_5$ is as defined below,

➢ **R$_3$** represents:
- a hydrogen atom,
- an aryl group, optionally substituted with an alkoxymethyl group,
- a cycloalkyl group,

or

- a heteroaryl group chosen from thienyl and pyridyl groups,

➢ **R$_4$** represents:
- a hydrogen atom,
- a linear group (C_1-C_3)alkyl, optionally substituted with a group -NR$_6$R$_6$' in which R$_6$ and R'$_6$ are as defined below or a group –NR$_7$R$_{7'}$' such that R$_7$ and R$_{7'}$ form, together with the nitrogen atom to which they are attached, a heterocycloalkyl comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,

➢ **R$_5$** represents:
- a hydrogen atom,
- a linear group (C_1-C_3)alkyl, optionally substituted with a pyridyl group,

  or
- an aromatic group chosen from aryl and pyridyl,

➢ **R$_6$** and **R'$_6$**, which may be identical or different, represent a hydrogen atom or a linear alkyl group,

in the form of the base or of an acid-addition or base-addition salt, in the manufacture of a medicament for treatment and prevention of cancers, especially carcinomas with a substantial degree of vascularization such as lung, breast, prostate, pancreatic, bowel, kidney and oesophageal carcinomas, cancers that induce metastases, such as bowel cancer, liver cancer and stomach cancer, melanomas, gliomas, lymphomas and leukaemias, and also thrombopenias.

15. Use of a Compound of formula (I)

(I)

in which:

the representation of the pyrazole ring indicates that the substituent R_4 may be borne either by the nitrogen alpha to the pyridine ring (I') or by the nitrogen alpha to the carbon bearing a substituent R_3 (I'') such that:



(I')

Either

(I'')

- **R_1** represents an aryl, pyridyl or pyrazolyl group optionally substituted with one or more substituents chosen from:
  - a halogen atom,
  - a $-CF_3$ group,
  - a cyano group,
  - a group $-NR_6R_6'$ in which R_6 and R_6' are as defined below,
  - a group $-NR_{10}R_{11}$ such that R_{10} and R_{11} form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom, optionally substituted with one or more substituents chosen from a halogen atom and a linear or branched alkyl group,

- a group $-CH_2NR_{10}R_{11}$ such that R_{10} and R_{11} form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,
- a group $-COR_{12}$ in which R_{12} represents a hydroxyl group or a group $-NR_6R_6'$, in which R_6 and R_6' are as defined below,
- a group $-CONR_7R_7'$ such that R_7 and R_7' form, together with the nitrogen atom to which they are attached, a heterocycloalkyl comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,
- a group $-(CH_2)_pNHSO_2CH_3$ in which p represents 0 or 1,
- a group $-OR_{13}$ in which R_{13} represents a linear group $(C_1$-$C_3)$alkyl,
- a group $(C_1$-$C_3)$alkyl,

Or R_1 represents a bicyclic group of formula A below:



(A)

in which R_8 and R_9 form, together with the carbon atoms to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom, an oxygen atom and a sulfur atom, optionally substituted with one or more linear alkyl groups,

- **R_2** represents:
  - a $-CF_3$ group,
  - a $-CHF_2$ group,
  - a –COOH group,
- or
  - a group $-CONHR_5$, in which R_5 is as defined below,

- **R_3** represents:
  - a hydrogen atom,
  - an aryl group, optionally substituted with an alkoxymethyl group,

- a cycloalkyl group,

or

- a heteroaryl group chosen from thienyl and pyridyl groups,

- **R_4** represents:
  - a hydrogen atom,
  - a linear group (C_1-C_3)alkyl, optionally substituted with a group -NR_6R_6' in which R_6 and R'_6 are as defined below or a group –$NR_7R_{7'}$' such that R_7 and $R_{7'}$ form, together with the nitrogen atom to which they are attached, a heterocycloalkyl comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,

- **R_5** represents:
  - a hydrogen atom,
  - a linear group (C_1-C_3)alkyl, optionally substituted with a pyridyl group,
    or
  - an aromatic group chosen from aryl and pyridyl,

- **R_6** and **R'_6**, which may be identical or different, represent a hydrogen atom or a linear alkyl group,

in the form of the base or of an acid-addition or base-addition salt, in the manufacture of a medicament for treatment and prevention cardiovascular diseases such as atherosclerosis, post-angioplasty restenosis, diseases associated with complications arising after the insertion of endovascular prostheses and/or aorto-coronary bypasses or other vascular grafts, cardiac hypotrophy, vascular complications of diabetes such as diabetic retinopathy, hepatic, renal and pulmonary fibroses, neuropathic pain, chronic inflammatory diseases such as rheumatoid arthritis or IBD, prostate hyperplasia, psoriasis, clear-cell acanthoma, osteoarthritis, achondroplasias (ACH), hypochondroplasias (HCH), TD (thanatophoric dysplasia), obesity, and macular degeneration, such as age-related macular degeneration (AMD).

CLAIMS

1. Compound corresponding to formula (I):

(I)

in which:

the representation of the pyrazole ring indicates that the substituent R_4 may be borne either by the nitrogen alpha to the pyridine ring (I') or by the nitrogen alpha to the carbon bearing a substituent R_3 (I'') such that:



(I')

Either

(I'')

- R_1 represents an aryl, pyridyl or pyrazolyl group optionally substituted with one or more substituents chosen from:
  - a halogen atom,
  - a $-CF_3$ group,
  - a cyano group,
  - a group $-NR_6R_6'$ in which R_6 and R_6' are as defined below,
  - a group $-NR_{10}R_{11}$ such that R_{10} and R_{11} form, together with the nitrogen atom to which they are attached, a saturated or

unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom, optionally substituted with one or more substituents chosen from a halogen atom and a linear or branched alkyl group,

- a group $-CH_2NR_{10}R_{11}$ such that R_{10} and R_{11} form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,
- a group $-COR_{12}$ in which R_{12} represents a hydroxyl group or a group $-NR_6R_6'$, in which R_6 and R_6' are as defined below,
- a group $-CONR_7R_7'$ such that R_7 and R_7' form, together with the nitrogen atom to which they are attached, a heterocycloalkyl comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,
- a group $-(CH_2)_pNHSO_2CH_3$ in which p represents 0 or 1,
- a group $-OR_{13}$ in which R_{13} represents a linear group $(C_1\text{-}C_3)$alkyl,
- a group $(C_1\text{-}C_3)$alkyl,

Or R_1 represents a bicyclic group of formula A below:



(A)

in which R_8 and R_9 form, together with the carbon atoms to which they are attached, a saturated or unsaturated heterocycle comprising one or more heteroatoms chosen from a nitrogen atom, an oxygen atom and a sulfur atom, optionally substituted with one or more linear alkyl groups,

- **R_2** represents:
  - a $-CF_3$ group,
  - a $-CHF_2$ group,
  - a –COOH group,
  - or
  - a group $-CONHR_5$, in which R_5 is as defined below,

- **R_3** represents:

- a hydrogen atom,
- an aryl group, optionally substituted with an alkoxymethyl group,
- a cycloalkyl group,

or

- a heteroaryl group chosen from thienyl and pyridyl groups,

➢ R_4 represents:

- a hydrogen atom,
- a linear group (C_1-C_3)alkyl, optionally substituted with a group -NR_6R_6' in which R_6 and R'_6 are as defined below or a group –$NR_7R_{7'}$ such that R_7 and $R_{7'}$ form, together with the nitrogen atom to which they are attached, a heterocycloalkyl comprising one or more heteroatoms chosen from a nitrogen atom and an oxygen atom,

➢ R_5 represents:

- a hydrogen atom,
- a linear group (C_1-C_3)alkyl, optionally substituted with a pyridyl group,

or

- an aromatic group chosen from aryl and pyridyl,

➢ R_6 and R'_6, which may be identical or different, represent a hydrogen atom or a linear alkyl group,

in the form of the base or of an acid-addition or base-addition salt.

2. Compounds of formula (I) according to Claim 1, with the exception of the following compounds:

3-(4-Fluorobenzyl)-1-methyl-6-[1-(2-methyl-2H-pyrazol-3-yl)-imidazo[1,5-a]pyridine-3-carbonyl]-1H-quinazoline-2,4-dione;

3-(4-Fluorobenzyl)-1-methyl-6-[1-(1-methyl-1H-pyrazol-4-yl)-imidazo[1,5-a]pyridine-3-carbonyl]-1H-quinazoline-2,4-dione;

3-(4-Fluorobenzyl)-1-methyl-6-[1-(1-methyl-1H-pyrazol-4-yl)-imidazo[1,5-a]pyridine-3-carbonyl]-1H-quinazoline-2,4-dione;

3-(4-Fluorobenzyl)-6-[1-(1-methyl-1H-pyrazol-4-yl)-imidazo[1,5-a]pyridine-3-carbonyl]-1-

propyl-1H-quinazoline-2,4-dione;
[6-(1-Bromo-2-methylindolizine-3-carbonyl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]acetic acid methyl ester;
[6-(1-Bromo-2-methylindolizine-3-carbonyl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]acetic acid tert-butyl ester;
6-(4-Fluoro-3-methoxycarbonylphenyl)-3-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid;
2-Fluoro-5-(3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzoic acid;
N,N-Dimethyl-3-(1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzamide;
N,N-Dimethyl-4-(1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzamide;
5-(1-Methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)nicotinonitrile;
6-Benzothiazol-5-yl-1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
1-Methyl-3-phenyl-6-(6-pyrrolidin-1-ylpyridin-3-yl)-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
1-Methyl-6-(6-morpholin-4-ylpyridin-3-yl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
3-(1-Methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzamide;
N-[4-(1-Methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzyl]methanesulfonamide;
1-Methyl-6-(1-methyl-1H-indol-6-yl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
N-[3-(1-Methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]methanesulfonamide;
4-Methyl-7-(1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-3,4-dihydro-2H-benzo[1,4]oxazine;
N-[3-(1-Methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzyl]methanesulfonamide;
6-(4-Methoxyphenyl)-1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
2-Fluoro-N-methyl-5-(1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzamide;
Dimethyl[3-(1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]amine;

6-[4-(3,5-Dimethylpyrazol-1-yl)phenyl]-1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;

1-Methyl-6-(3-morpholin-4-ylmethylphenyl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;

5-(1-Methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)nicotinonitrile;

4-(1-Methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzoic acid;

N,N-Dimethyl-4-(1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzamide;

N,N-Dimethyl-3-(1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzamide;

1-Methyl-6-(6-morpholin-4-ylpyridin-3-yl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;

6-(6-Methoxypyridin-3-yl)-1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;

1-Methyl-3-phenyl-6-(6-pyrrolidin-1-ylpyridin-3-yl)-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;

1-Methyl-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;

6-Benzothiazol-5-yl-1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;

N,N-Dimethyl-4-(3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzamide;

6-(4-Morpholin-4-ylphenyl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;

6-(6-Morpholin-4-ylpyridin-3-yl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;

6-(6-Methoxypyridin-3-yl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;

6-(3-Morpholin-4-ylphenyl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;

N-Methyl-3-(3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzamide;

N-[3-(3-Phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]methanesulfonamide;

3-Phenyl-6-(3-piperidin-1-ylphenyl)-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;

2-Fluoro-N-methyl-5-(3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzamide;

5-(3-Phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)nicotinonitrile;

2-Fluoro-5-(1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzoic acid;

2-Amino-5-(4-difluoromethyl-2-methyl-2H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;

Dimethyl[4-(3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]amine;

4-(3-Phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenylamine;
6-(4-Methoxyphenyl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
in the form of the base or of an acid-addition or base-addition salt.

3. Compounds of formula (I) according to Claim 1, characterized in that $\mathbf{R_2}$ represents a group:

- $-CHF_2$, except when R_4 located on the nitrogen alpha to R_3 represents a methyl group and R_3 represents a hydrogen atom,
- –COOH,

or

- $-CONHR_5$, in which R_5 represents a hydrogen atom or a linear group $(C_1\text{-}C_3)$alkyl, optionally substituted with a pyridyl group or an aromatic group chosen from aryl and pyridyl,

in the form of the base or of an acid-addition or base-addition salt.

4. Compounds of formula (I) according to any one of Claims 1 to 3, characterized in that $\mathbf{R_1}$ represents an aryl, pyridyl or pyrazolyl group, optionally substituted with one or more substituents chosen from:

- a halogen atom,

and

- a group $-COR_{12}$, in which R_{12} represents a hydroxyl group,

in the form of the base or of an acid-addition or base-addition salt.

5. Compounds of formula (I) according to Claims 1 to 4, characterized in that $\mathbf{R_1}$ represents an aryl group, in the form of the base or of an acid-addition or base-addition salt.

6. Compounds of formula (I) according to any one of Claims 1, 2, 4 and 5, characterized in that $\mathbf{R_2}$ represents:

- a $-CF_3$ group,
- a $-CHF_2$ group,
- a –COOH group,

or

- a group $-CONHR_5$, in which R_5 represents a hydrogen atom or a

linear group (C_1-C_3)alkyl, optionally substituted with a pyridyl group or an aromatic group chosen from aryl and pyridyl,

in the form of the base or of an acid-addition or base-addition salt.

7. Compound of formula (I) according to one of the preceding claims, characterized in that it is chosen from the following compounds:

6-(4-Methoxyphenyl)-1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;

Dimethyl[3-(1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]amine;

N-Methyl-3-(3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzamide;

[4-(4-Difluoromethyl-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]pyrrolidin-1-ylmethanone;

4-Difluoromethyl-6-(1-methyl-1H-pyrazol-4-yl)-3-phenyl-1H-pyrazolo[3,4-b]pyridine;

4-Difluoromethyl-6-(3,5-dimethyl-1H-pyrazol-4-yl)-3-phenyl-1H-pyrazolo[3,4-b]pyridine;

4-Difluoromethyl-3-phenyl-6-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine;

4-Difluoromethyl-6-(6-methoxypyridin-3-yl)-3-phenyl-1H-pyrazolo[3,4-b]pyridine;

[3-(4-Difluoromethyl-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]pyrrolidin-1-ylmethanone;

4-Difluoromethyl-3-phenyl-6-(3-piperidin-1-ylphenyl)-1H-pyrazolo[3,4-b]pyridine;

6-(4-Amino-3-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid;

6-(4-Amino-3-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid;

6-(4-Amino-3-methoxyphenyl)-3-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid methylamide;

6-(4-Amino-3-methoxyphenyl)-3-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide; compound with trifluoroacetic acid;

6-(4-Amino-3-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid methylamide;

4-(4-Amino-3-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid methylamide;

6-(4-Amino-3-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide;

6-(4-Amino-3-methoxyphenyl)-3-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid;

6-(4-Amino-3-methoxyphenyl)-2-methyl-2H-pyrazolo[3,4-b]pyridine-4-carboxylic acid;

6-(4-Amino-3-methoxyphenyl)-1-methyl-3-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid;

6-(4-Amino-3-methoxyphenyl)-1-methyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid;

6-(4-Amino-3-methoxyphenyl)-2-methyl-2H-pyrazolo[3,4-b]pyridine-4-carboxylic acid

amide;
5-(4-Carbamoyl-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-2-fluorobenzoic acid;
2-Amino-5-(4-carbamoyl-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzoic acid;
6-(4-Amino-3-cyanophenyl)-3-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide;
6-(4-Amino-3-cyanophenyl)-3-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide;
6-(4-Amino-3-cyanophenyl)-2-methyl-2H-pyrazolo[3,4-b]pyridine-4-carboxylic acid;
6-(4-Amino-3-cyanophenyl)-3-thiophen-2-yl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide;
6-(4-Amino-3-cyanophenyl)-3-cyclopropyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid;
5-(4-Carbamoyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-2-fluorobenzoic acid;
6-(3-Cyano-4-fluorophenyl)-3-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide;
5-(4-Difluoromethyl-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-2-fluorobenzoic acid;
2-Fluoro-5-(3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
2-Amino-5-(4-difluoromethyl-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
2-Fluoro-5-(3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzoic acid;
2-Amino-5-(1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
2-Amino-5-(1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
6-(3-Carbamoyl-4-fluorophenyl)-3-pyridin-3-yl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide;
5-(4-Difluoromethyl-2-methyl-2H-pyrazolo[3,4-b]pyridin-6-yl)-2-fluorobenzonitrile;
6-(1H-Indol-6-yl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
5-(3-Phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-1,3-dihydrobenzimidazol-2-one;
6-(4-Amino-3-cyanophenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid phenylamide;
6-(4-Amino-3-cyanophenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid (pyridin-2-ylmethyl)amide;
6-(4-Amino-3-cyanophenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid pyridin-2-ylamide;
6-(4-Amino-3-cyanophenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid pyridin-3-ylamide;

6-(4-Amino-3-cyanophenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid pyridin-4-ylamide;

5-(4-Difluoromethyl-2-methyl-2H-pyrazolo[3,4-b]pyridin-6-yl)-2-fluorobenzamide;

5-(4-Difluoromethyl-1-methyl-3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-2-fluorobenzonitrile;

2-Amino-5-(2-methyl-3-phenyl-4-trifluoromethyl-2H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;

6-(1H-Benzimidazol-5-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid phenylamide;

6-(1H-Benzimidazol-5-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid pyridin-2-ylamide;

6-(1H-Benzimidazol-5-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid (pyridin-3-ylmethyl)amide;

6-(2-Oxo-2,3-dihydro-1H-benzimidazol-5-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid phenylamide;

2-Amino-5-(4-difluoromethyl-1-methyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;

3-(4-Difluoromethyl-1-methyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;

4-(4-Difluoromethyl-1-methyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenylamine;

2-Amino-5-[2-(2-dimethylaminoethyl)-3-phenyl-4-trifluoromethyl-2H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile;

2-Amino-5-(4-difluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;

2-Amino-5-[1-(2-dimethylaminoethyl)-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile;

2-Amino-5-[2-(2-morpholin-4-ylethyl)-3-phenyl-4-trifluoromethyl-2H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile;

2-Methoxy-5-(1-methyl-3-phenyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)nicotinonitrile;

2-Amino-5-(4-difluoromethyl-1-methyl-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;

4-(4-Difluoromethyl-1-methyl-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenylamine;

[3-(4-Difluoromethyl-1-methyl-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]dimethylamine;

2-Amino-5-[3-phenyl-1-(2-piperidin-1-ylethyl)-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile;

Dimethyl{3-[3-phenyl-1-(2-piperidin-1-ylethyl)-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl}amine;

2-Amino-5-[4-difluoromethyl-2-(2-dimethylaminoethyl)-2H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile;
2-Amino-5-[4-difluoromethyl-2-(2-morpholin-4-ylethyl)-2H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile;
2-Amino-5-[4-difluoromethyl-1-(2-dimethylaminoethyl)-3-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile;
2-(2-Morpholin-4-ylethyl)-6-(3-morpholin-4-ylmethylphenyl)-4-trifluoromethyl-2H-pyrazolo[3,4-b]pyridine;
Dimethyl{3-[1-(2-morpholin-4-ylethyl)-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl}amine;
5-[1-(2-Morpholin-4-ylethyl)-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl]nicotinonitrile;
5-[1-(2-Morpholin-4-ylethyl)-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl]nicotinamide;
2-Amino-5-(2-methyl-4-trifluoromethyl-2H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
1-Methyl-6-(3-morpholin-4-ylmethylphenyl)-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
2-Amino-5-(1-methyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
Dimethyl[3-(1-methyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]amine;
Dimethyl[3-(3-phenyl-2-propyl-4-trifluoromethyl-2H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]amine;
2-Amino-5-[4-difluoromethyl-2-(2-piperidin-1-ylethyl)-2H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile;
2-Amino-5-(4-difluoromethyl-3-pyridin-3-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
2-Amino-5-(4-difluoromethyl-2-propyl-2H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
2-Amino-5-(4-difluoromethyl-3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
1-Methyl-6-(3-morpholin-4-ylmethylphenyl)-3-pyridin-3-yl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
2-Amino-5-[4-difluoromethyl-3-(3-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]benzonitrile;
2-Amino-5-(2-propyl-4-trifluoromethyl-2H-pyrazolo[3,4-b]pyridin-6-yl)benzonitrile;
6-(3-Morpholin-4-ylmethylphenyl)-2-propyl-4-trifluoromethyl-2H-pyrazolo[3,4-b]pyridine;
Dimethyl[3-(2-propyl-4-trifluoromethyl-2H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]amine;
6-(3-Morpholin-4-ylmethylphenyl)-1-propyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
6-(4-Methoxyphenyl)-1-propyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;
5-[3-(3-Methoxyphenyl)-1-methyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl]nicotinonitrile;

3-(3-Methoxyphenyl)-1-methyl-6-(3-morpholin-4-ylmethylphenyl)-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine;

{3-[3-(3-Methoxyphenyl)-1-methyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl}dimethylamine;

3-(3-Methoxyphenyl)-6-(4-methoxyphenyl)-1-methyl-4-trifluoromethyl-1H-pyrazolo[3,4-b]pyridine.

8. Process for preparing the compounds of formula (I) according to Claim 1, in which R_2 represents a group $-CHF_2$ or $-CF_3$; R_1, R_3 and R_4 are as defined previously, with the exception of a hydrogen atom, characterized in that:

- the compound of formula (XV) is subjected to an iodination reaction in the presence of N-iodosuccinimide in order to obtain the compound of formula (XVIII),
- the compound of formula (XVIII) is then subjected to an alkylation reaction in the presence of a halogenated derivative of formula R_4-X in order to obtain the compounds of formulae (XIX) and (XX),
- the compounds of formulae (XIX) and (XX) are separately subjected, in the presence of a palladium catalyst, a ligand and a base, to a reaction with phenylboronic or heteroarylboronic derivatives or phenylboronate esters or heteroarylboronate esters according to a Suzuki coupling, in order to obtain the compounds of formulae (XXI) and (XXII),
- the compounds of formulae (XXI) and (XXII) are separately subjected, in the presence of a palladium catalyst, a ligand and a base, to a reaction with phenylboronic or heteroarylboronic derivatives or phenylboronate esters or heteroarylboronate esters according to a Suzuki coupling, in order to obtain the compound of formula (I) in which R_2 represents a group $-CHF_2$ or $-CF_3$; R_1, R_3 and R_4 are as defined previously, with the exception of R_3 and R_4 representing a hydrogen atom.

9. Process for preparing the compounds of formula (I) according to Claim 1, in which R_2 represents a group $-CHF_2$ or $-CF_3$, R_1 and R_3 are as defined previously, with the exception of a hydrogen atom, characterized in that:

- the compound of formula (XVIII) is subjected to an alkylation reaction in the presence of a protecting group P in order to obtain the compound of formula (XXIII),
- the compound of formula (XXIII) is subjected to a reaction with phenylboronic or heteroarylboronic derivatives or phenylboronate esters or heteroarylboronate esters

according to a Suzuki coupling, in order to obtain the compound of formula (XXIV),

- the compound of formula (XXIV) is subjected to a reaction with phenylboronic or heteroarylboronic derivatives or phenylboronate esters or heteroarylboronate esters according to a Suzuki coupling, in order to obtain the compound of formula (XXV),

- the compound of formula (XXV) is subjected to a deprotection reaction in order to obtain the compound of formula (I) in which R_2 represents a group $-CHF_2$ or $-CF_3$ and R_1 and R_3 are as defined previously.

10. Medicament, characterized in that it comprises a compound of formula (I) according to any one of Claims 1 to 7 or a pharmaceutically acceptable acid-addition or base-addition salt of this compound.

11. Compounds of formula (I) according to any one of Claims 1 to 7, as medicaments.

12. Pharmaceutical composition, characterized in that it comprises a compound of formula (I) according to any one of Claims 1 to 7, a pharmaceutically acceptable salt of this compound, and also at least one pharmaceutically acceptable excipient.

13. Use of a compound of formula (I) according to any one of Claims 1 to 7, for the preparation of a medicament for treating and preventing diseases necessitating a modulation of the b-FGFs.

14. Combination of a compound according to any one of Claims 1 to 7 with one or more anticancer active principles and/or with a radiotherapy and/or with any anti-VEGF therapy.

15. Compound according to any one of Claims 1 to 7, for its use in the treatment and prevention of cancers, especially carcinomas with a substantial degree of vascularization such as lung, breast, prostate, pancreatic, bowel, kidney and oesophageal carcinomas, cancers that induce metastases, such as bowel cancer, liver cancer and stomach cancer, melanomas, gliomas, lymphomas and leukaemias, and also thrombopenias.

16. Compound according to any one of Claims 1 to 7, for its use in combination with one or more anticancer active principles and/or with a radiotherapy and/or with any anti-VEGF therapy.

17. Compound according to any one of Claims 1 to 7, for its use in the treatment and prevention of cardiovascular diseases such as atherosclerosis, post-angioplasty restenosis, diseases associated with complications arising after the insertion of endovascular prostheses and/or aorto-coronary bypasses or other vascular grafts, cardiac hypotrophy, vascular complications of diabetes such as diabetic retinopathy, hepatic, renal and pulmonary fibroses, neuropathic pain, chronic inflammatory diseases such as rheumatoid arthritis or IBD, prostate hyperplasia, psoriasis, clear-cell acanthoma, osteoarthritis, achondroplasias (ACH), hypochondroplasias (HCH), TD (thanatophoric dysplasia), obesity, and macular degeneration, such as age-related macular degeneration (AMD).